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Abstract
An improved monoclonal antibody immunoaffinity chromatography/high-pressure  liquid chromatography/ 
ftuorescence detection method was developed to measure aftatoxin (AF) exposure by quantifying AFM 1 in 
human and rat urine samples.
Analysis of different amounts of various AF metabolites showed that the immunoaffinity resin was highly 
selective for aftatoxin 81 (AFB1), AFB2, and AFM 1• Recovery of added AFs increased with the amount of 
immunoaffinity resin and was virtually complete within the range of 0.01-10 ng of AFM 1 by using 7 ml of 
resin. The detection limit of this method is 0.5 pglml urine. Rats dosed with tritiated AFB 1 excreted in their 
urine tritiated AFM., among other AF metabolites, as indicated by chemical derivative confirmation and 
cochromatography  with authentic AFM 1 and agreement of radioactivity and ftuorescence quantitation. A 
linear dose-response relationship was found over the range of 0.05-50 p.glkg of body weight/day. Two humans 
dosed with 1.0 µ.g of pure AFB 1 excreted 6-7% of the dose asurinary AFM 1 over 5-7 days. Pooled urine 
samples from 30 men from each of 69 rural counties in mainland  China and 16 survey areas in Taiwan, with 
two villages per county or area, were analyzed with this improved method (170 villages total). The correlation 
coefficient of urinary excretion of AFM 1 compared between villages within all 85 survey areas was 0.50 (P < 
0.001). Sixty-five % of the samples contained detectable concentrations of AFM 1 with an average excretion of 
3.1 ng/12 h. Assuming an excretion rate of 2-6%, this AFM 1 excretion corresponds to a very low average daily 
AF consumption of 0.1-0.3 p.g/day (possible range, 0-11 p.g/day). Patterns of urinary excretion of AFM 1 were 
similar in mainland China and Taiwan
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Abstract 
An improved monoclonal antibody immunoaffinity 
chromatography/high-pressure  liquid chromatography/ 
ftuorescence detection method was developed to measure 
aftatoxin (AF) exposure by quantifying AFM 1 in human 
and rat urine samples. 
Analysis of different amounts of various AF 
metabolites showed that the immunoaffinity resin was 
highly selective for aftatoxin 81 (AFB1), AFB2, and 
AFM 1• Recovery of added AFs increased with the amount 
of immunoaffinity resin and was virtually complete 
within the range of 0.01-10 ng of AFM 1 by using 7 ml of 
resin. The detection limit of this method is 0.5 pglml 
urine. 
Rats dosed with tritiated AFB 1 excreted in their 
urine tritiated AFM., among other AF metabolites, as 
indicated by chemical derivative confirmation and 
cochromatography  with authentic AFM 1 and agreement 
of radioactivity and ftuorescence quantitation. A linear 
dose-response relationship was found over the range of 
0.05-50 p.glkg of body weight/day. Two humans dosed 
with 1.0 µ.g of pure AFB 1 excreted 6-7% of the dose as 
urinary AFM 1 over 5-7 days. 
Pooled urine samples from 30 men from each of 69 
rural counties in mainland  China and 16 survey areas in 
Taiwan, with two villages per county or area, were 
analyzed with this improved method (170 villages total). 
The correlation coefficient of urinary excretion of AFM 1
compared between villages within all 85 survey areas was 
0.50 (P < 0.001). Sixty-five % of the samples contained 
detectable concentrations of AFM 1 with an average 
excretion of 3.1 ng/12 h. Assuming an excretion rate of 
2-6%, this AFM 1 excretion corresponds to a very low 
average daily AF consumption of 0.1-0.3 p.g/day 
(possible range, 0-11 p.g/day). Patterns of urinary 
excretion of AFM 1 were similar in mainland China and 
Taiwan. 
. 
Introduction 
AFs2 are a group of toxic secondary metabolites produced by 
the fungus Aspergillus flavus/parasiticus, which may contam- 
inate a variety of human and animal food crops ( 1). The most 
common and most biologically active of these fungal metabo- 
lites is AFB 1 (2). Upon ingestion and absorption of AFB 1, a 
series of metabolites is produced, primarily in the liver. These 
include AFepollide• AFM 1, AFP 1, AFQ 1,AFB28, and aflatoxicol 
(3). 
AF has been declared a human carcinogen by an IARC 
working group (4). In contrast to several earlier ecological 
studies (5-9), our comprehensive ecological study of 48 coun- 
ties in rural China reported no relationship (r = -0.17) be- 
tween AF exposure and a wide range of primary liver cancer 
mortality rates (10). 
This conclusion was challenged ( 11, 12) on grounds that 
the methodology ( 13) to analyze the urine samples for oxidized 
AFB 1 metabolites as a means of assessing AF exposure was 
inadequate. Because of this criticism, we developed a  much 
more sensitive and specific method using monoclonal immu- 
noaffinity column resin and HPLC to measure AFM 1 in a more 
recent collection of urine samples from 16 survey sites of 
Taiwan and 69 rural counties in mainland China (including 
samples from the original  48 counties  reported  earlier). 
Materials and Methods 
Experimental Design of Mainland China Ecological Study. 
The study design for the cross-sectional ecological survey per- 
formed in 1983 was described by Chen et al. (14). The 1989 
study was essentially identical to the 1983 study, with a few 
important differences. Only those details relevant to the data 
presented in this report are described here. The original 65 
survey counties were chosen in 1983 by a multistage sampling 
procedure in order to obtain a wide geographical scatter and to 
encompass the full range of mortality rates for seven of the 
more common cancers in China. These counties were located in 
25 provinces  and autonomous regions and widely dispersed 
throughout the mostly rural regions of mainland China. In 1989, 
an extra four counties from the more remote regions of China 
were added to the study (two from Xinjiang Autonomous 
Region and two from Ningxia Autonomous Region), bringing 
the total to 69 counties. The additional counties contained high 
percentages of national minority groups and extended the 
breadth of dietary practices for the entire survey. In 1983 two 
xiangs (subcounties) were randomly selected within each 
county, and within each xiang, one village was randomly cho- 
sen, yielding a total of  130 villages. Survey xiangs were re- 
stricted to those within 4 h travel time of the county laboratory. 
Within each of the  villages,  25 households  were  randomly 
2 The abbreviations used are: AF. afla1oxin; DMSO, dimethylsulfoxide; HPLC. 
high-perfonnance liquid chromalography ; TEAF. triethylamrnonium formate. 
 
 
 
 
 
selected from an official registry of residences. From a random 
one-half of the households, one male, age 35-64 years, was 
then invited to participate in the study. If the selected subject 
was absent or declined to participate (<l% of those initially 
identified), then another subject in a neighboring household 
was selected. The same individuals participating in the 1983 
survey were invited to participate in the 1989 survey. If the 
subjects were no longer available (by reason of death, illness, 
translocation, unwillingness to participate , or falling outside the 
age group of the study). then new participants were randomly 
selected . Five additional households per village were randomly 
selected for inclusion so that from each county 60 male subjects 
participated, yielding a total of 4140 subjects (69 counties, 30 
males from each of 2 villages per county). This study was 
approved by the Cornell University Committee on Human 
Subjects. 
Experimental Design of 1989 Taiwan Ecological Study. A 
stratified multistage random sampling procedure was used to 
select 16 survey areas in Taiwan. The sampling procedure was 
based on the level of urbanization . ethnicity. crude cancer 
mortality rates, population size, and geographical location. 
These survey areas included coastal, inland, mountain, and 
plains areas. In each survey area, two xiangs. in each xiang, two 
villages, and in each village, 33 males, ages 35-64, were 
chosen randomly . If the number of subjects was not enough to 
meet the intended number, then additional subjects in neigh- 
boring households were selected. The total number of partici- 
pating male subjects was 1056 (16 survey areas, 33 males from 
each of two xiangs). When added to the survey subjects of 
mainland China, a total of 5196 adult males were included , 
compared to 3250 adult males in the 1983 survey. most of 
whom participated in both surveys. 
Human Urine Collection and Storage. Each male was in- 
vited to donate a urine sample. In 1983 this was a 4 h collection 
after an oral dose, for other purposes, of riboflavin and ascorbic 
acid. In 1989, an overnight 12 h urine sample was collected 
from 7 p.m. to  7 a.m. A 5% aliquot of each sample was 
combined into a pool for each xiang, then was stored at -20° 
within 4 h of collection of the last sample. The samples were 
shipped on dry ice either to the Institute of Nutrition and Food 
Hygiene in Beijing or to Academia Sinica in Taipei, where the 
samples were stored at -30°C. In 1991 and 1992, the pooled 
samples from 1989 were shipped to Cornell University (Ithaca, 
NY), and were stored at -80°C. 
Human AFB 1 Dosing. This experiment was designed to de- 
termine the sensitivity of the new urinary AFM 1 method in 
detecting small levels of AFB 1 intake. After collecting a com- 
plete 24 h urine sample, two men were administered 1.0 µg 
AFB 1 in 100 µl of tricaprylin oil with a meal. Complete daily 
urine collections were taken over the next I 0 days. The subjects 
consumed no peanut products during the collection period. 
Urine volumes were recorded , and urine specimens were frozen 
at -20°C. Within I week the samples were defrosted and 
analyzed for urinary AFM 1• Other random urine samples, col- 
lected before and after this period, contained no detectable 
AFM 1• This procedure was approved by the Cornell University 
Committee on Human Subjects. 
Urinary AFM 1 Extraction . Urinary AFM 1 was analyzed by a 
method resulting from major modifications of the method of 
Groopman et al. (15). All procedures were carried out at room 
temperature. The preparation of monoclonal immunoaffinity 
resin was described by Groopman et al. (16). A stored urine 
sample was defrosted and mixed well. Ten ml were removed 
and adjusted to pH 4 by using 0.1 mol/liter HCI. Individual C 18 
Sep-Pak cartridges (Millipore Corp.) were prepared by sequen- 
tial elution with 5 ml each of 5, 80, JOO, and 5% methanol in 
water. The urine was applied to the prepared Sep-Pak cartridge 
at a flow rate of 5 ml/min, and the effluent was discarded. The 
Sep-Pak cartridge was then rinsed with 5 ml of 5% methanol. 
The AFs were eluted with l0 ml of 80% methanol, and the 
eluate was collected in a glass conical 15-ml centrifuge tube 
and evaporated under nitrogen in a 50°C water bath. After the 
eluate was evaporated to 0.3-0.5 ml, 0.3 ml of 0.1 moUliter 
HCI was added, mixed, and cooled to room temperature, and 
then 0.5 ml of I mol/liter ammonium formate, pH 4.5, was 
added. The volume was adjusted to IO ml with water, and the 
sample was applied to a 7 ml monoclonal immunoaffinity 
column and allowed to elute under gravity. For the subsequent 
elutions, a small aquarium pump was used to apply slight 
pressure to the top of the column. The column was washed with 
two 14-ml volumes of PBS, pH 7.4, and then 14 ml of water. 
The AFs were eluted with 14 ml of 70% DMSO in water; this 
was followed with two more washes of 14 ml PBS. The DMSO 
fraction and the two following PBS washes were combined and 
diluted to 84 ml with water to dilute out the DMSO. This 
sample was applied to a conditioned Sep-Pak cartridge, pre- 
pared as described above, to remove DMSO. The AFs were 
eluted with 8 ml of 80% methanol, collected in a glass conical 
15 ml-centrifuge tube, and then evaporated under nitrogen in a 
50°C water  bath to 0.1 ml. To this solution 100 µI of 0.1 
mol/liter HCI was added, which was then mixed and adjusted to 
pH 3.0 with 200 µI of 1.0 mol/liter ammonium formate, pH 4.5. 
The sample was then adjusted to 0.5 ml with 0.01 mol/liter 
TEAF and submitted to HPLC analysis. 
Urinary AFM 1 HPLC Analysis. The HPLC system was a 
gradient model 334 from Beckman Instruments (Fullerton, CA) 
with a model FL-750BX fluorescence detector (McPherson 
Division of Schoeffel Instruments Corporation, Acton, MA). 
The excitation wavelength was 365 nm with an interference 
UT-I filter. The emission filter was a long-band pass filter. The 
column was an Ultramex 5 µm C 18 250 x 4.6 mm column 
(Phenomenex, Inc., Torrance, CA) and was heated with a 
column temperature controller (Timberline, Inc., Boulder, CO). 
A model SP 4290 integrator (Spectra Physics, San Jose, CA) 
was attached. The mobile phase was 13% ethanol and 3% 
methanol in TEAF, and the flow rate was 0.6 ml/min. A typical 
system pressure of 50-70 bar was observed. A 0.2 µm precol- 
umn filter (Upchurch Scientific, Oak Harbor, WA) was 
changed daily. Authentic AF standards were obtained from 
Sigma Chemical Co. (St. Louis, MO). AFN7G was a gift from 
Dr. John Groopman (Johns Hopkins University , Baltimore. 
MD). 
For each human urine sample, two subsamples of 0.25 ml 
each were prepared for HPLC analysis. One subsample was run 
as is, and a second was run after adding an amount of AFM 1 
standard approximately equal to that which appeared in the first 
chromatogram. The retention time of AFM 1 was about 12 min. 
Calculations were made by comparing the integrated peak 
areas for AFM 1 external standards with peak areas for the 
sample AFM 1 areas. Excretion of AFM 1 per 12 h was calcu- 
lated by multiplying by the appropriate volume of the 12 h urine 
pools. 
Rat Experimental Protocol. Male Fisher-344 rats were 
purchased at 6 weeks of age from Charles River Breeding 
Laboratories, Inc. (Wilmington, MA) and housed singly in 
wire-bottomed metabolic cages in a temperature- and humidity- 
controlled environment with a 12-h-light/12-h-dark photo- 
period. Food and water were available ad libitum. Animals 
 
 
 
 
 . 
 
 
 
were fed AIN-76A diet ( 17), and at 7 weeks of age had attained 
body weights between 160and 180 g. They were then randomly 
assigned into seven groups of five animals per group. Six 
groups were dosed daily Monday through Friday by oral gavage 
for 2 weeks and then killed. One group was dosed with AFB2, 
AFG 1, and AFG2 for I week each on Monday through Friday, 
and after 3 weeks they were killed . The dose for each of these 
AFs was 50 µg/kg of body weight/day. 3H-AFB 1 (Moravek 
Biochemicals , Brea, CA) and unlabeled AFB2, AFG 1, and 
AFG2 were administered in tricaprylin oil. Among the six 
groups dosed for 2 weeks, a control group of rats was treated 
with only tricaprylin oil, whereas the other five were treated 
with 3H-AFB 1 at dosages of 0.005, 0.05, 0.5, 5, and 50 µg/kg 
of body weight/day . 
Rat Urine Collection. Quantitative collection of urine samples 
was accomplished by washing down the metabolic cage sur- 
faces with JO ml of water each day. The average daily sample 
contained approximately JO ml of water and JO ml of urine. 
Three-day urine samples from 9:00 a.m. Wednesday morning 
through 9:00 a.m. Saturday morning of each week were pooled 
and kept frozen at -80°C. Generally, I ml of pooled urine was 
adjusted to pH 4 with 0.1 mol/liter HCI. The volume was 
adjusted to JO ml by adding water and analyzed for urinary 
AFM 1 as described above. Radioactivity was quantitated with 
Liquiscint scintillation fluid (National Diagnostics, Somerville, 
NJ) in a model LS 7000 liquid scintillation counter (Beckman 
Instruments). 
Confirmatory Test for Urinary AFM 1• A chemical deriva- 
tive confirmatory test for AFM t was performed on several 
human and rat urine samples to confirm the identity of AFM 1 
by this new method. This test was originally developed to 
identify AFB 1 in food  (18), although later it was used to 
identify AFM 1 in human urine (19). In the present study, JO 
suspected AFM 1-positive urine samples from mainland China 
with different levels of AFM 1 and I rat urine sample from each 
of the AFB 1-dosed groups were selected for AFM 1 confirma- 
tion . When the urine was ready for HPLC injection, it was 
adjusted from 0.50 to 0.75 mL with O.oJ mol/liter TEAF. A 
0.25 ml subsample was evaporated just to dryness in a 50°C 
water bath under nitrogen to remove residual water. Ethanol 
(0.25 ml) was added, and the vial was placed in a 50°C water 
bath for 30 min to evaporate the ethanol under nitrogen. Con- 
centrated formic acid (0.2 ml) and I drop of thionyl chloride 
were added to the residue. The mixture was allowed to stand at 
room temperature for 5 min and then was evaporated to dryness 
under the same conditions as described above. The residue was 
dissolved in 0.25 ml O.QJ mol/liter TEAF and injected onto the 
HPLC column. Authentic AFM 1 standard dissolved in ethanol 
also was treated with formic acid and thionyl chloride in the 
same manner as the test samples for HPLC analysis. 
 
 
Table 2   Recovery of variable amounts of added AFM 1 in JO ml of urine 
(%  + SD) from the immunoaffinity column of variable sizes 
 
Volume of antibody 
(ml) 
AFM 1  added 
(ng) 
No. of 
replicates 
Recovery 
(%) 
4 50 6 89 :!: 2 
4 20 2 80 :!: 4 
4 10 15 39 :!: 3 
6 10 2 84 :!: 4 
7 10 15 98 :!: 5 
7 5 I 90 
7 2 2 108 :!: 3 
7           1 7 88 :!: 4 
7 0.02 9 96 :!: 7 
 
 
 
Statistical Methods. Minitab statistical software, Release 8 
(Minitab Inc., State College, PA) was used to assess simple 
statistic  parameters. 
 
Results 
Development of the AFM 1 Method. This newly  modified 
method was tested initially by examining the recovery of var- 
ious AFs added to water (Table I). Using the 4-ml immunoaf- 
finity column recommended in the original method of Groop- 
man et al. (15), only AFB 1, AFB2,and AFM 1 bound well to the 
resin and were eluted by DMSO. Recoveries of AFG 1 and 
AFP 1 in the DMSO fraction were poor and only reached 25%. 
Other AF metabolites , including AFN7G, were completely 
eluted before application of the DMSO. Recovery of added 
AFM 1, using three different column volumes, is shown in Table 
2. In 4 ml of resin, percentage of recovery decreased when 
decreasing amounts of AFM 1 were added to the column. In 
contrast, recovery improved when increasing amounts of resin 
were used. Recovery of AFM 1 reached 96% when using 7 ml 
of resin and as little as JO pg of AFM 1 per JO-mL urine sample. 
Subsequently , I 0 ml of urine and 7 ml of resin were used in all 
analyses, unless otherwise stated. 
A HPLC chromatogram of I 0 pg AFM 1 standard is shown 
in Fig. I. Although this very small quantity of pure AFM 1 
standard was clearly measurable, urine samples, in contrast, 
contained considerable amounts of interfering fluorescent ma- 
terial. To minimize the background fluorescence, the urine 
sample volume was reduced from the original 25 to JO ml. With 
these conditions, the detection limit of this method was about 
2.5 pg of AFM 1 per injection, or about 0.5 pg/ml of urine. 
Among every 20 human subjects, one human control urine 
sample spiked with JO pg AFM 1 was analyzed. A total of JO 
spiked samples showed a mean recovery of 96% (87-109%). In 
addition,  12 human samples from China containing varying 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. /. Test for AFM, standanl. AFM 1 standard was dissolved in 0.25 ml 
ethanol and injected on the HPLC. The peak was obtained at 12.86 min of 
retention lime. The amount of standanl injected was 10 pg. 
 
 
 
amounts of AFM t, from undetectable to 108 ng/12 h, were 
analyzed in duplicate. The analysis was performed blind . 
Amounts of AFM 1 between first and second runs were highly 
correlated (r = 0.96), with a coefficient of variation of about 
10%. 
Rat Urinary Excretion of AFM 1• No potentially  interfering 
peaks were detected in the urine samples of the control animals 
or in the urine samples from animals dosed with AFB2, AFG 1, 
or AFG2• About 10% of the administered radioactivity was 
excreted in the urine for each of the [3H]AFB 1-dosed groups. 
Between 37 and 68% of the urinary  radioactivity eluted in the 
void and wash volumes, reflecting the nonretention of many of 
the AFB 1  metabolites  by the resin (see Table  1). 
 
 
 
 
AFM 1 was detected in the urine samples of all AFB 1- 
dosed rats except those in the lowest dosage group. Approxi- 
mately 1-2% of dietary AFB 1 was excreted as urinary AFM 1. 
There was a linear relationship between the logarithm of the 
dose between 0.05-50 µg/kg of body weight/day and the log- 
arithm of urinary AFM 1 in ng/day (r = 0.91; P < 0.001). The 
suspected AFM 1 peak of the rat urine samples was chromato- 
graphically identical to the suspected AFM 1 in the human urine 
samples and to the AFM, standard. Moreover, added AFM 1 
standard cochromatographed as one peak with the suspected 
AFM,. And finally, quantitation of AFM 1 either by fluores- 
cence detection or by radiotracer content in the collected peak 
was also in good agreement. 
Confirmatory Tests for AFM 1 in Human Urine. Selected 
human urine samples prepared for HPLC analysis were each 
divided into three subsamples. The first untreated subsample 
was chromatographed, and a peak with a retention time similar 
to authentic AFM 1 standard was observed (Fig. 2). In the 
second subsample, added AFM 1  standard cochromatographed 
with the suspected AFM 1 peak (Fig. 3). The suspected AFM 1 
peak of the third subsample was selectively derivatized by 
thionyl chloride treatment (Fig. 4). When this procedure was 
performed on the radiolabeled rat samples, not only did the 
fluorescent suspected AFM peak disappear, but most (about 
93%) of the suspected AFM 1 radioactivity was not recovered at 
the expected retention time. The results of these various con- 
firmatory tests provided evidence that the suspected AFM 1 
peak of the urine samples was the same compound as the 
standard AFM 1• 
Excretion of AFM 1 by Dosed Humans. Two adult human  
 
Fig. 2.  ConfinnatOI)' tests for AFM, in human urine. A suspected AFM, peak 
was eluted at 12.74 min. The original peak contained 16 pg AFM 1• 
 
 
 
males were administered 1.0 µg AFB 1,and urine was collected 
over the next 10 days until no further AFM 1 was detected. One 
subject excreted 5.6% of the initial AFB 1 as AFM 1 over a 
period of 5 days, whereas the second subject excreted 6.6% of 
the AFB, dose as AFM 1 over a period of 7 days (Table 3). 
Maximum excretion occurred during the second day after dos-
ing. Total body clearance half-lives were approximately  0.9 
days. Urine samples collected before and after this period 
contained no AFM 1• 
Analysis of AFM 1 in Human Urine. A total of 138 urine 
samples from mainland China and 32 from Taiwan representing 
pools for each village were analyzed (Fig. 5). Eighty-eight 
pooled samples (64%) from mainland China and 21 (66%) from 
Taiwan showed measurable levels of urinary AFM 1• The mean 
and highest levels of AFM 1 excretion rates in mainland China 
was 3.2 and 108 ng/12 h, respectively, whereas the mean and 
highest levels in Taiwan were 2.7 and 17 ng/12 h, respectively . 
Urinary AFM 1 excretion rates were not significantly different 
between mainland China and Taiwan. 
With the exclusion of the single highest outlier value, the 
correlation between urinary AFM 1 measurements from the two 
xiangs within each of the 69 counties in rural China was r = 
0.50 (P < 0.001), thus indicating considerable homogeneity of 
AF exposure within each survey site and providing validation 
of the AF exposure procedures. However, AF exposure in 1989 
(as urinary AFM 1) was not correlated with AF exposure in 1983 
 
 
(as urinary oxidized AF metabolites) (r = -0.04), thus reflect- 
ing either a considerable variability of AF exposure over time 
or the modification in methodology . 
 
Discussion 
The immunoaffinity column method did not perform as well as 
previously indicated (15, 16, 20). Not all metabolites were 
retained on the resin; some (AFN7G and AFQ 1) were eluted 
either in the void volume or with the PBS and water eluants 
(Table 1). However, AF binding patterns, as indicated by elu- 
tion order, still reflected  the sequence of binding  constants 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.   Confirmatory tests for AFM 1 in human urine. To a second aliquot. 50 pg 
AFM 1 standard was added. and then the aliquot was analyzed by HPLC. 
 
 
 
observed for the "2811" antibody originally used in the prep- 
aration of the column (16). AFB 1, AFM 1, and AFB2 bound well 
Fig. 4. Confirmatory tests for AFM 1 in human urine. The third aliquot was 
treated with formic acid and thionyl chloride and injected on the high-perfor- 
mance liquid chromatograph . 
 
 
 
and were eluted quantitatively with DMSO. The difference in 
AFN7G binding between this and previous studies suggests that 
 
 
 
slight changes in procedure or in batches of resin material may 
be responsible for major alterations in performance of the 
immunoaffinity column procedure. 
In light of the previous demonstration that urinary AFMt 
is highly correlated with AFB 1 intake (15, 19-21), we pro- 
ceeded to explore and to adopt four major changes  in  the 
methodology earlier used in studies in Guangxi (20), The Gam- bia 
(15), and Shanghai (22). These changes included the fol- lowing: 
First, the chief analyte of interest was changed from AFN7G to 
AFM 1. In addition to the poor recovery of AFN7G from the 
 
 
immunoaffinity column, AFM 1 was also chosen be- cause of 
its later retention on the HPLC column, thus minimiz- ing the 
interference resulting from the earlier eluting peaks; Second, 
the earlier HPLC method relied on a mobile phase gradient. 
This modified method, which was less encumbered with 
early peak interference, employed isocratic elution, which 
typically yields more reproducible peak areas and shorter anal- 
ysis times; Third, the immunoaffinity column volume was 
increased from 4 to 7 ml, thus obtaining reproducible recovery 
of the extremely low levels of AFM 1 usually found in urine 
samples; and fourth, AFM 1, which is more fluorescent than 
AFN7G and which is present at about twice the concentration of 
AFN7G in human urine (15, 20), was analyzed by a specialized 
McPherson model FL-750BX fluorescence detector, which 
uses a 200-W xenon-mercury lamp that had a strong emission 
peak at about the 365 nm absorption maximum that is charac- 
teristic of AF metabolites. The matching of this emission peak 
and  the  absorption  maximum  of  AFs  contributed  to  the 
   
 
 
 
Enhancement by more than JOO-fold of the detection 
limit of this method when pure standards between this 
and earlier methods were compared (22). In studies 
validating the use of AFN7G as a biomarker of AFB 
1 intake (15, 19, 20), daily AFM 1 excretion also 
exhibited a relatively strong and highly significant 
correlation (r = 0.55-0.66) with AFB 1 intake, al- 
though this correlation was somewhat less than that for 
AFN7G. All of these considerations and modifications 
served to enhance the sensitivity of the present 
method to assess AF exposure, particularly at low 
doses. 
The detection limit of the method used for 
studies vali- dating AFN7G and AFM 1 excretion as 
biomarkers of AFB, intake in Africa and China was 
approximately 40 pg/ml urine for both metabolites (15, 
20, 22). However, Weaver and Groop- man (23) 
recently developed still-newer methods for urinary 
AFN7G based on immunoaffinity column sample 
preparation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Dislribution of average uri- 
nary AFM concentrations in counties 
in China. 
 
 
 
 
 
(ng excreted in 12 hours) 
 
 
and either synchronous fluorescence spectroscopy or HPLC 
quantitation. For HPLC quantitation, the AFN7G-containing 
fraction was collected from one HPLC run, then subjected to 
acid hydrolysis and subsequent quantitation as AFB 1-diol by 
another HPLC run. The detection limit of this method for pure 
AFN 7G standard was about 1.5 pg/ml. Our method, when 
comparing standard solutions of AF in water, exhibited a de- 
tection limit of 0.2 pg/ml. In another recent method also using 
an immunoaffinity column and HPLC but using postcolumn 
derivatization, the detection limit was 6.8 pg/ml (24). 
Our study appears to be the first in which humans were 
intentionally dosed with pure AFB 1• The enhanced sensitivity 
of this new method allowed for very small doses of AFB 1 to be 
consumed. The quantity consumed is equivalent to the amount 
of AFB 1 found in a sandwich made with peanut butter contain- 
ing the maximum legal limit of AFB 1 in the United States (20 
ppb). The two adult male subjects (Z. C. and M. R.) who 
consumed AFB 1 gave similar urinary excretion patterns . The 
percentage of the original dose of AFB 1 found in the urine was 
6-7% over a period of 5-7 days, which is higher than the 1-4% 
earlier estimated by us and others (15, 19, 21) for shorter 
collection periods. Randomly collected urine samples from 
these same two subjects showed no evidence of AFB 1 expo- 
sure. 
The purpose of the rat experiment was to confirm the 
biological source, the chemical identity, and the quantitation of 
AFM 1 in urine. Based on the lack of interfering peaks from 
AFB2, AFG 1, or AFG2 and the dose-response relationship 
between AFB 1 dose and AFM 1 excretion, we are confident that 
the source of the suspected AFM 1 peak is derived from the dose 
of AFB 1 and is not from other AF metabolites. The percentage 
of administered radiolabel derived from the ingested AFB 1 
found in the urine, the percentage of urinary AF that binds to 
the affinity column, and the percentage of dosed AFB 1 excreted 
as urinary  AFM 1  all confirm  similar percentages  found  in 
earlier studies (13, 16). Fluorescence detection and radioactiv- 
ity measurements provided similar estimates of AFM 1 concen- 
trations; moreover, formic acid-thionyl chloride derivatization 
of the peak provided additional confirmation of its identity. 
AF contamination of foods ( I ) observed over time has 
long been known to be exceptionally variable. Thus, it would be 
expected that urinary excretion of AF metabolites by individ- 
uals consuming those foods also would be unusually variable, 
although somewhat less so. With a biological half-life of about 
I day, the urinary excretion of biomarkers such as AFM 1 could 
reflect AFB 1 intake averaged over 1-3 days. In the ecological 
study described herein, 170 pooled urine samples, each com- 
prising 30 men, were analyzed, thus yielding approximately 
30-90 man-days of integrated exposure for each data point, or 
approximately 5,100-15,300 total man-days of exposure for 
the entire survey. This represents substantial improvement in 
sampling stability over previous studies, although seasonal and 
yearly changes in AF exposure still remain underrepresented. It 
is difficult to predict how these results would compare to 
surveys performed in other seasons or years. The sensitivity of 
the method reported herein allows for the detection of I subject 
out of 30 in a pool consuming about I µ.g of AFB 1 once during 
the 3 days prior to urine sampling and pooling. Thus, the 
combination of sampling stability and analytical method sen- 
sitivity greatly improves the ability to assess AF exposure. 
In the survey in mainland China and Taiwan, the urinary 
excretion of AFM 1 was very low, with one-third of the samples 
below the detection limit. Assuming that the 12 h collection 
represents one-half of the daily excretion and that 2-5% of 
AFB 1 consumed in the diet is excreted as AFM 1, the average 
intake of AFB 1 in mainland China and Taiwan was about 
0.1-0.3 µ.g/day; the highest estimated level of intake was about 
11 µ.g/day. Most of these intakes are considerably below those 
from high-primary liver cancer areas such as The Gambia, 
Guangxi, and the Philippines (15, 19, 20), where average in- 
 
 
 
 
 
takes have been reported to range from 12 to 77 µ.g/day. They 
are also below previous reports for Taiwan of total urinary 
aflatoxin excretion (25). 
Because these low estimates of AFB 1 intake were puz- 
zling, we reanalyzed a collection of samples blind about I year 
later to confirm our earlier analyses. Correspondence between 
replicates was excellent. As noted earlier, validation of this 
method also was examined by several other analytical proce- 
dures, including assessment of AFM 1 excretion by rats and 
humans. A possible explanation of these low levels is deterio- 
ration of the AFM 1 during the 4 years between collection and 
analysis. No direct evidence is available on this point. Wild et 
al. (26) contend that AF-albumin adducts in sera are stable 
when kept frozen at -70°C for as long as 15 years. Our own 
experience with the samples was that no decay occurred over I 
year between the first and second testing of a subset of samples. 
Thus, we are confident that these estimates of AF intake are 
reliable. It also should be noted that this estimate of relatively 
low AF intakes corresponds to the findings of two other reports 
from China (27, 28), both of which used an ELISA method to 
directly measure AFB 1 intake and which gave mean intakes of 
0.1 and 3.4 µ.g/day for subjects residing in Fusui county. In a 
study of aflatoxin exposure in The Gambia, Wild et al. (29) 
found an average daily intake of 1.4 µ.g/day. In a survey of 
chemical contaminants of food in four areas of China, the 
average intake of AFB 1 was 0.15 µ.g/day (30). In our survey 
county, com consumption, a common source of AFB contam- 
inants in food, decreased about 40% between 1983 and 1989, 
according to preliminary dietary intake data from our ecological 
survey. We have no further explanation for the relatively high 
estimates of AFB 1 intake from other studies except to suggest 
that the populations under investigation may have been biased 
toward very high intake areas. Although the intakes from this 
survey are unusually low, the highly significant correlation 
between villages within the same counties supports the geo- 
graphic diversity of AFB exposure. 
In conclusion, a reliable, sensitive, selective, reproducible 
method for measuring urinary AFM 1 has been developed. An- 
imal studies confirm the source, identity, and quantitation of the 
AFM 1• The excretion rate from two intentionally dosed humans 
was 5-6%. AFM 1 excretion across mainland China and Taiwan 
was very low (3.1 ng/12 h), with good agreement between 
villages from the same county and similar results from main- 
land China and Taiwan. AFB, intake was calculated to average 
0.1-0.3 µ.g/day (possible range, 0-11 µ.g/day). 
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